165 related articles for article (PubMed ID: 32221162)
1. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).
Huang CF; Lai HC; Chen CY; Tseng KC; Kuo HT; Hung CH; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang JF; Dai CY; Chuang WL; Tsai PC; Peng CY; Yu ML
Am J Gastroenterol; 2020 Aug; 115(8):1226-1235. PubMed ID: 32221162
[TBL] [Abstract][Full Text] [Related]
2. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort).
Hsu WF; Tsai PC; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
J Gastroenterol Hepatol; 2021 Oct; 36(10):2884-2892. PubMed ID: 33963615
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
5. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
[TBL] [Abstract][Full Text] [Related]
6. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).
Yeh ML; Hung CH; Tseng KC; Lai HC; Chen CY; Kuo HT; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang CF; Huang JF; Dai CY; Chuang WL; Tsai PC; Peng CY; Liu CJ; Yu ML
Hepatol Int; 2021 Oct; 15(5):1109-1121. PubMed ID: 34365587
[TBL] [Abstract][Full Text] [Related]
8. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
9. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M
J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609
[TBL] [Abstract][Full Text] [Related]
10. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
Leone S; Prosperi M; Costarelli S; Nasta P; Maggiolo F; Di Giambenedetto S; Saracino A; Di Pietro M; Gori A
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1511-20. PubMed ID: 27272121
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
12. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
13. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
[TBL] [Abstract][Full Text] [Related]
14. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
15. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
16. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.
Su TH; Liu CJ; Tseng TC; Chou SW; Liu CH; Yang HC; Wu SJ; Chen PJ; Chen DS; Chen CL; Kao JH
Aliment Pharmacol Ther; 2019 Feb; 49(3):331-339. PubMed ID: 30592071
[TBL] [Abstract][Full Text] [Related]
17. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
[TBL] [Abstract][Full Text] [Related]
18. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.
Hsu WF; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Tsai PC; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
Sci Rep; 2020 Mar; 10(1):5372. PubMed ID: 32214132
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
